Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.

	Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.
	Selvaggi, G.4; Wu, Y.5; Wang, Z.6; Wu, G.1; Poddubskaya, E.2; Reck, M.7; Mok, T.8; Chiappori, A.9; Lee, D. H.3; Breder, V.10
刊名	JOURNAL OF THORACIC ONCOLOGY
	2021-03-01
卷号	16
关键词	ALK NSCLC ensartinib
ISSN号	1556-0864
WOS研究方向	Oncology ; Respiratory System
语种	英语
出版者	ELSEVIER SCIENCE INC
WOS记录号	WOS:000631349600306
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/121756]
专题	中国科学院合肥物质科学研究院
作者单位	1.Tongji Med Coll, Union Hosp, Huazhong, Peoples R China 2.Sechenov Univ, Clin Ctr Oncol, Moscow, Russia 3.Asan Med Ctr, Seoul, South Korea 4.Xcovery Holdings Inc, Palm Beach Gardens, FL USA 5.Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China 6.Beijing Canc Hosp, Beijing, Peoples R China 7.Airway Res Ctr North Arcn, Lung Clin, Grosshansdorf, Germany 8.Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Peoples R China 9.H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA 10.Minist Hlth Russian Federat, NN Blokhin Natl Med Res Ctr Oncol, Moscow, Russia
推荐引用方式 GB/T 7714	Selvaggi, G.,Wu, Y.,Wang, Z.,et al. Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.[J]. JOURNAL OF THORACIC ONCOLOGY,2021,16.
APA	Selvaggi, G..,Wu, Y..,Wang, Z..,Wu, G..,Poddubskaya, E..,...&Wakelee, H. A..(2021).Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3..JOURNAL OF THORACIC ONCOLOGY,16.
MLA	Selvaggi, G.,et al."Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.".JOURNAL OF THORACIC ONCOLOGY 16(2021).